Publications Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies September 27, 2019 Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR. ESMO Annual Congress. . https://www.annalsofoncology.org/article/S0923-7534(19)59501-1/pdf Authors:Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR Sources:ESMO Annual Congress Read the research SharePosted inComparative effectivenessSkin cancer More publicationsMay 2026Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancerMay 2026Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumabMay 2026Machine learning risk stratification in a US-based database to identify subgroups of patients with head and neck cancer who benefit from adding chemotherapy to pembrolizumab
May 2026Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancer
May 2026Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab
May 2026Machine learning risk stratification in a US-based database to identify subgroups of patients with head and neck cancer who benefit from adding chemotherapy to pembrolizumab